Study Highlights Readmit Factors Post Atrial Flutter Ablation

This article originally appeared here.
Share this content:
Study Highlights Readmit Factors Post Atrial Flutter Ablation
Study Highlights Readmit Factors Post Atrial Flutter Ablation

THURSDAY, Aug. 17, 2017 (HealthDay News) -- Recognition of factors associated with early readmission for patients after atrial flutter (AFL) ablation is necessary for reducing costs and improving quality of life, according to a study published online Aug. 11 in the Journal of Cardiovascular Electrophysiology.

Byomesh Tripathi, M.D., from Mount Sinai St Luke's-Roosevelt Hospital in New York City, and colleagues examined factors associated with early readmissions following AFL ablation. The National Readmission Database 2013 to 2014 was used to derive the study cohort.

The researchers found that the readmission rate was 18.19 percent among 5,552 patients (1,010 patients with 1,396 readmissions). Heart failure, atrial fibrillation, atrial flutter, respiratory complications, infections, bleeding, and stroke/transient ischemic attack were common etiologies for readmission (12.23, 11.13, 8.93, 9.42, 7.4, 7.39, and 1.89 percent, respectively). Preexisting heart failure, chronic pulmonary disease, anemia, malignancy, weekend admission (versus weekday admission), and length of stay of at least five days were significant multivariate predictors of 90-day readmission (hazard ratios, 1.30, 1.37, 1.23, 1.87, 1.23, and 1.39, respectively). Half of the readmissions occurred within 30 days of discharge.

"Identifying high-risk patients, careful discharge planning, and close follow-up post-discharge can potentially reduce readmission rates in AFL ablation patients," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »